Mek inhibitors in the treatment of virus diseases

Abstract

The present invention relates to MEK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The MEK inhibitors can be used in the prevention and/or treatment of viral infection. MEK inhibitors in combination with neuraminidase inhibitor compounds are capable of displaying one or more beneficial therapeutic effects in the treatment of viral diseases.

1 . A MEK inhibitor or a pharmaceutically acceptable salt thereof for use in a method for the prophylaxis and/or treatment of a viral disease, wherein said MEK inhibitor is selected from the group consisting of PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, AS703026, PD98059 and PD184352, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 1  wherein the viral disease is an infection caused by a negative RNA strand virus. 
     
     
         3 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 2 , wherein the virus is influenza virus. 
     
     
         4 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 3 , wherein the influenza virus is influenza A virus or influenza B virus. 
     
     
         5 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 1 , wherein the MEK inhibitor a pharmaceutically acceptable salt thereof is administered in combination with a neuraminididase inhibitor or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 5 , wherein the MEK inhibitor or a pharmaceutically acceptable salt thereof is administered contemporaneously, previously or subsequently to the neuraminididase inhibitor a pharmaceutically acceptable salt thereof. 
     
     
         7 . The MEK inhibitor or a pharmaceutically acceptable salt thereof for the use according to  claim 5  wherein the neuraminidase inhibitor is selected from oseltamivir, oseltamivir phosphate, zanamivir or peramivir a pharmaceutically acceptable salt thereof. 
     
     
         8 . A pharmaceutical composition comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof and a neuraminidase inhibitor or a pharmaceutically acceptable salt thereof. 
     
     
         9 . A pharmaceutical composition comprising a MEK inhibitor and a neuraminidase inhibitor or a pharmaceutically acceptable salt thereof for use as a medicament. 
     
     
         10 . The pharmaceutical composition of  claim 8  wherein the MEK inhibitor is selected from PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, AS703026, PD98059 and PD184352, or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The pharmaceutical composition of  claim 8 , wherein the neuraminidase inhibitor is selected from oseltamivir, oseltamivir phosphate, zanamivir or peramivir. 
     
     
         12 . The pharmaceutical composition as defined in  claim 8  for use in the prophylaxis and/or treatment of a viral disease. 
     
     
         13 . A method for treating a subject having a viral infection, comprising administering to a subject the MEK inhibitor or pharmaceutically acceptable salt thereof of  claim 1  wherein administering treats a viral infection in the subject.